Jurisdictional guides

This subtopic provides a range of international guidance.

The Lexology Panoramic guides, curated by leading lawyers and law firms, provide a view of laws and regulations in multiple jurisdictions

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

Unjust enrichment, NOM clauses and advisory scope (RMK v Euronav)

Commercial analysis: In RMK Maritime (Europe) Ltd and another company v CMB.Tech NV (previously known as Euronav NV), the Commercial Court dismissed a quantum meruit claim for nearly US$11.7m brought by RMK seeking payment for alleged extra-contractual services. Mr Justice Henshaw held that: (1) The services fell within the scope of the parties’ advisory agreement, and (2) In any event, unjust enrichment could not be used to circumvent a detailed contractual framework reinforced by a no oral modification (NOM) clause and an express variation mechanism. The decision is a reaffirmation of contractual primacy in sophisticated commercial relationships. It provides important guidance on the interaction between unjust enrichment and contract, the legal effect of NOM clauses, and the risks of broadly drafted advisory scopes. For commercial practitioners, the case underscores a simple point: if additional services are to be paid for, they must be agreed and documented at the time. This article is written by Zara Yusuf, barrister at Three Stone.

EU Cybersecurity Package 2026: Cybersecurity Act 2 and targeted NIS2 amendments

EU Law analysis: On 20 January 2026, the European Commission published a new ‘Cybersecurity Package’ consisting of a proposed Regulation referred to as ‘Cybersecurity Act 2’ of the ‘Revised EU Cybersecurity Act’ that would replace Regulation (EU) 2019/881, the current EU Cybersecurity Act (‘CSA’) and a proposal for a Directive amending Directive (EU) 2022/2555, the EU NIS 2 Directive (‘NIS2’). The proposals aim to address non-technical ICT supply-chain risks, reform the EU Cybersecurity Certification Framework, and make targeted changes to NIS 2. Written by Dr Henrik Hanssen, attorney and counsel at Hogan Lovells International LLP.

Commission publishes January 2026 harmonised standards update under the medical devices Regulations

The European Commission has published two new Implementing Decisions updating the references of harmonised standards under the EU medical devices framework. On 28 January 2026, the Commission adopted Implementing Decision (EU) 2026/193 under Regulation (EU) 2017/745 on medical devices and Implementing Decision (EU) 2026/197 under Regulation (EU) 2017/746 on in vitro diagnostic medical devices. The Decisions amend earlier Implementing Decisions to reflect newly developed and revised harmonised standards, the voluntary application of which confers a presumption of conformity with the relevant regulatory requirements.

MHRA updates GLP-1 prescriber guidance on pancreatitis risks

The Medicines and Healthcare products Regulatory Agency (MHRA) has updated product information for healthcare professionals and patients to highlight the small risk of severe acute pancreatitis associated with glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists. The MHRA advised clinicians and patients to be alert to symptoms such as severe and persistent abdominal pain, nausea and vomiting, and to seek urgent medical attention if these occur. It noted that acute pancreatitis is a recognised but infrequent adverse effect of these medicines, which are authorised for the treatment of type 2 diabetes and, for some products, weight management and cardiovascular risk reduction. MHRA reaffirmed that GLP-1 medicines are generally safe and effective for their approved uses. It also stressed the importance of reporting suspected adverse reactions through the Yellow Card scheme and confirmed ongoing research through the Yellow Card Biobank to assess whether genetic factors may influence individual risk.